The present disclosure is directed to methods of treating fibrotic conditionsby administration of TR.beta. agonists Thedisclosure provides methods wherein the abnormal deposition of extracellularmatrix components, such as collagen, keratin, or elastin,is reduced, either through interaction of TR.beta. agonists with TGF-.beta.¨dependent inflammatory pathways, or by other mechanisms, therebyameliorating fibrotic symptoms
